AR022673A1 - Formulaciones de dosis orales - Google Patents
Formulaciones de dosis oralesInfo
- Publication number
- AR022673A1 AR022673A1 ARP990104841A ARP990104841A AR022673A1 AR 022673 A1 AR022673 A1 AR 022673A1 AR P990104841 A ARP990104841 A AR P990104841A AR P990104841 A ARP990104841 A AR P990104841A AR 022673 A1 AR022673 A1 AR 022673A1
- Authority
- AR
- Argentina
- Prior art keywords
- solvate
- dosage forms
- oral dose
- products
- dose formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Esta invencion proporciona formas de dosis oral discretas, típicamente tabletas o cápsulas, que contienen (2S, 3S, 5R)-2-(3,5-difluorofenil)-3,5-dimetil-2-morfolinol o una sal fisiologicamente aceptable o solvato del mismo, o un solvato de dicha sal,y una cantidad de estabilizante efectiva de ácido algínico.Estas formas de dosis son utiles para prevenir o tratar el trastorno o depresion hipercinética de la deficiencia de la atencion o en el tratamiento de laadiccion a productos que contienen nicotina, especialmente productos que contienen tabaco, tales como los que ayudan al cese de fumar.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10211298P | 1998-09-28 | 1998-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR022673A1 true AR022673A1 (es) | 2002-09-04 |
Family
ID=22288187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990104841A AR022673A1 (es) | 1998-09-28 | 1999-09-24 | Formulaciones de dosis orales |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1117407A1 (es) |
| JP (1) | JP2002525328A (es) |
| KR (1) | KR20010075385A (es) |
| CN (1) | CN1328459A (es) |
| AR (1) | AR022673A1 (es) |
| AU (1) | AU6087399A (es) |
| BR (1) | BR9914096A (es) |
| CA (1) | CA2345638A1 (es) |
| CZ (1) | CZ20011142A3 (es) |
| HU (1) | HUP0103459A2 (es) |
| IL (1) | IL142054A0 (es) |
| MA (1) | MA26693A1 (es) |
| NO (1) | NO20011555D0 (es) |
| PE (1) | PE20001087A1 (es) |
| PL (1) | PL346877A1 (es) |
| TR (1) | TR200100863T2 (es) |
| WO (1) | WO2000018406A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1220673A2 (en) * | 1999-10-13 | 2002-07-10 | Glaxo Group Limited | Morpholinol derivatives for the treatment of obesity |
| DE102008047910A1 (de) | 2008-09-19 | 2010-03-25 | Molkerei Meggle Wasserburg Gmbh & Co. Kg | Tablettierhilfsstoff auf Laktose- und Cellulosebasis |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4597969A (en) * | 1982-04-05 | 1986-07-01 | Merck Sharp & Dohme | Stabilization of unstable drugs or food supplements |
| GB8924528D0 (en) * | 1989-10-31 | 1989-12-20 | Wellcome Found | Heterocyclic pharmaceutical compounds,preparation and use |
-
1999
- 1999-09-23 MA MA25782A patent/MA26693A1/fr unknown
- 1999-09-24 CZ CZ20011142A patent/CZ20011142A3/cs unknown
- 1999-09-24 HU HU0103459A patent/HUP0103459A2/hu unknown
- 1999-09-24 BR BR9914096-9A patent/BR9914096A/pt not_active IP Right Cessation
- 1999-09-24 PL PL99346877A patent/PL346877A1/xx unknown
- 1999-09-24 CN CN99813675A patent/CN1328459A/zh active Pending
- 1999-09-24 TR TR2001/00863T patent/TR200100863T2/xx unknown
- 1999-09-24 KR KR1020017003874A patent/KR20010075385A/ko not_active Application Discontinuation
- 1999-09-24 WO PCT/EP1999/007117 patent/WO2000018406A1/en not_active Application Discontinuation
- 1999-09-24 CA CA002345638A patent/CA2345638A1/en not_active Abandoned
- 1999-09-24 AU AU60873/99A patent/AU6087399A/en not_active Abandoned
- 1999-09-24 EP EP99947420A patent/EP1117407A1/en not_active Withdrawn
- 1999-09-24 JP JP2000571924A patent/JP2002525328A/ja active Pending
- 1999-09-24 AR ARP990104841A patent/AR022673A1/es unknown
- 1999-09-24 IL IL14205499A patent/IL142054A0/xx unknown
- 1999-09-27 PE PE1999000976A patent/PE20001087A1/es not_active Application Discontinuation
-
2001
- 2001-03-27 NO NO20011555A patent/NO20011555D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PL346877A1 (en) | 2002-03-11 |
| CA2345638A1 (en) | 2000-04-06 |
| TR200100863T2 (tr) | 2001-07-23 |
| BR9914096A (pt) | 2001-07-31 |
| CZ20011142A3 (cs) | 2001-09-12 |
| JP2002525328A (ja) | 2002-08-13 |
| WO2000018406A1 (en) | 2000-04-06 |
| HUP0103459A2 (hu) | 2002-01-28 |
| NO20011555L (no) | 2001-03-27 |
| PE20001087A1 (es) | 2000-10-20 |
| EP1117407A1 (en) | 2001-07-25 |
| AU6087399A (en) | 2000-04-17 |
| IL142054A0 (en) | 2002-03-10 |
| MA26693A1 (fr) | 2004-12-20 |
| KR20010075385A (ko) | 2001-08-09 |
| NO20011555D0 (no) | 2001-03-27 |
| CN1328459A (zh) | 2001-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2549642A1 (en) | Effervescent oral opiate dosage forms and methods of administering opiates | |
| AR059723A2 (es) | Composicion de altas dosis de ibandronato | |
| ES2062392T3 (es) | Medicamentos que comprenden salmeterol y fluticasona. | |
| CR8352A (es) | Formulaciones farmaceuticas, procedimientos y pautas de dosificacion para el tratamiento y prevencion de sindromes coronarios agudos | |
| BE2011C013I2 (es) | ||
| UY27553A1 (es) | Formulaciones farmacéuticas de 5,7,14-triazatetraciclo(10.3.1.02,11.04,9)-hexadeca-2/11),3,5,7,9-pentaeno | |
| EG25381A (en) | Dry powder inhalation device for the simultaneous administration of more than one medicament. | |
| SV1998000148A (es) | Arilpiperazinas que tienen actividad en el receptor de serotonina 1a ref. x-11334 | |
| IL128723A0 (en) | Pharmaceutical compositions containing rar antagonists and rxr agonists | |
| BRPI0512241A (pt) | inalador utilizando casulos | |
| IL151628A0 (en) | Combination therapies with vascular damaging activity | |
| CL2004000452A1 (es) | Uso de un compuesto antiepileptico que contiene propiedades de alivio del dolor y dos o mas compuestos del grupo formado por antagonista del nmda selectivos de subtipo, analgesicos, nsaid, y combinaciones de ellos, para la preparacion de un medicamen | |
| CY1105545T1 (el) | Θεραπεια στατινης για ενισχυση της διατηρησης νοητικης λειτουργιας | |
| AR022673A1 (es) | Formulaciones de dosis orales | |
| MX9203361A (es) | Composiciones farmaceuticas que contienen cloruro de galio. | |
| UY26073A1 (es) | Formas de dosis orales | |
| ES2182504T3 (es) | Bifenilsulfonilcianamidas, procedimiento para su preparacion y su utilizacion como medicamento. | |
| SE0203817D0 (sv) | New composition | |
| AR032479A1 (es) | Nuevas composiciones farmaceuticas que contienen epinastina y pseudoefedrina | |
| RU2205636C1 (ru) | Средство для профилактики вредного воздействия табачного дыма и других продуктов горения | |
| GT200000160A (es) | Combinacion para el tratamiento de la dependencia de alcohol y las drogas, que contiene un antagonistaopioide y un modular del complejo del receptor de nmda. | |
| AR002040A1 (es) | Soluciones farmacéuticas salinas no inorgánicas para administración endonasal conteniendo una calcitonina natural o modificada y excipientes orgánicos. | |
| ECSP961857A (es) | Composiciones refrescantes | |
| AR047999A1 (es) | Forma de dosificacion oral efervescente de fentanilo y metodos de administracion de fentanilo |